Novartis AG (NYSE:NVS) could cut around 130 jobs in Switzerland as it relocates laboratory activities and ends small-scale biologics production at its Kleinbasel site in Basel. The company plans to move laboratories supporting biological cell banks, analytical testing and technical development to its main Basel campus by the end of 2028. Small-scale biologics production at Kleinbasel is expected to end by the end of 2027.
The move is part of a previously announced plan to establish a new biologics technical development center at the main Basel campus. Novartis AG said the relocation is also linked to individual leases at the Kleinbasel site expiring in 2029. The company intends to shift the affected production activities to existing biologics drug-substance facilities elsewhere in its European manufacturing network. The potential job cuts are subject to an information and consultation process. Novartis said it will support affected employees through measures including job centers, early retirement and an extended social plan.
A Leaner Footprint Could Support Long-Term Growth
The relocation could ultimately improve Novartis AG’s operating efficiency by consolidating research, testing and technical development activities at its main Basel campus. Rather than simply eliminating the Kleinbasel operations, the company is creating a dedicated biologics technical development center, which suggests that the strategy is focused on concentrating resources in higher-value activities.
The decision also appears to be planned rather than a reaction to weak demand. Novartis first announced the relocation in 2022, and the timing is tied partly to lease expirations in 2029. That reduces the likelihood that the 130 potential job cuts signal a sudden deterioration in the company’s underlying business.
From a manufacturing perspective, Novartis AG is not abandoning biologics production altogether. The company plans to transfer the small-scale production activities to existing facilities elsewhere in Europe. Concentrating production at established sites could provide greater scale and reduce duplication across the manufacturing network.
There is also a broader growth story supporting the bull case. Novartis recently reported positive late-stage results for remibrutinib in relapsing multiple sclerosis. The Wall Street Journal reported that analysts see the drug as potentially generating billions of dollars in annual sales, giving Novartis another potential growth driver as it replaces revenue affected by patent expirations.
The Restructuring Could Expose New Challenges
The most obvious concern is that the restructuring could reinforce worries about Novartis AG reducing its manufacturing footprint in Switzerland. Around 130 positions could be affected out of approximately 200 employees currently working at the Kleinbasel site. While the company characterizes the move as a relocation and consolidation, the loss of jobs could generate negative sentiment around its commitment to Swiss operations.
The move also comes alongside substantial investment in U.S. manufacturing. Novartis plans to spend $23 billion to build and expand 10 U.S. facilities over five years, partly reflecting pressure on pharmaceutical companies to increase domestic manufacturing. Investors could therefore question whether Switzerland will become relatively less important to Novartis’ manufacturing strategy over time.
There are also execution risks. Moving laboratories and production activities can involve restructuring expenses, employee disruption and the potential loss of experienced personnel. The company will need to ensure that the transition does not affect the quality, timing, or reliability of biologics development and production.
Finally, the company’s increased focus on new medicines carries its own risks. Although remibrutinib’s recent Phase III results were encouraging, Novartis AG still faces competition and regulatory hurdles before the drug can reach its full commercial potential. Analysts have noted that more detailed data will be needed to determine how it compares with competing treatments.
Conclusion
The bull case appears stronger from a long-term fundamental perspective. The potential 130 job cuts look more like part of a planned consolidation than evidence of a weakening business. Novartis AG is moving biologics-related activities to its main Basel campus, building a new technical development center and transferring production to existing European facilities rather than abandoning the business.
For investors, the bigger story is capital and resource allocation. Novartis is streamlining its physical footprint while directing resources toward strategic R&D and larger manufacturing facilities. If the consolidation produces efficiency gains without disrupting operations, the restructuring could be modestly positive for the company over the longer term. The main risks are execution costs, further reductions in Swiss manufacturing, and the challenge of turning Novartis’ pipeline investments into commercially successful medicines. For now, the Basel restructuring looks more like strategic optimization than a fundamental warning sign, particularly given the company’s recent positive clinical developments.
READ NEXT: Brown-Forman (BF-B) Struggles with Weak Spirits Demand and Canada Headwinds and PG&E (PCG)’s $2 Billion Spending Deferral Raises Questions Over its Growth Outlook
This article is originally published at Insider Monkey.
